18 June 2009
Stakeholders say that Europe and its rare disease patients will benefit from a series of political commitments that Health Ministers from all 27 member states have signed up to by adopting a Council Recommendation on European Action in the Field of Rare Diseases.
 |
17 June 2009
Following the World Health Organization?s (WHO) declaration last week of an influenza pandemic, vaccine makers in Europe and China as well as world health agencies are stepping up efforts toward rapid development and approval of an effective vaccine.
|
16 June 2009
Following changes to European legislation, the European Medicines Agency (EMEA) will make public some of the information in EudraCT — a database that contains information on clinical trials in Europe.
|
12 June 2009
The European Commission?s (EC) Directorate-General for Enterprise and Industry (EC–DG Enterprise) announced last week that it will not continue preparing a commission directive on good manufacturing practices (GMPs) for certain excipients.
|
12 June 2009
The outcome of a concept paper by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), which sought the input of stakeholders on the review and consolidation of the UK medicines legislation, has been published.
|
12 June 2009
A new Faculty of Translational Medicine has been established in London (UK) that will increase support for, and enhance collaboration among, researchers as they search for new treatments and diagnostic tests for a range of diseases and conditions.
|
12 June 2009
India-based Kemwell plans to build a new biopharmaceutical manufacturing plant in Bangalore (India) in a strategic collaboration with Boehringer Ingelheim (BI, Germany).
|
12 June 2009
"EU governments need to ensure fast generic medicines uptake as market access and low market volume in key EU countries is still a real problem and is having a major negative impact on patient access to more affordable treatments."
|
12 June 2009
The European Medicines Agency (EMEA) has agreed to an EU-wide recall of all the remaining batches of Merck Serono's Raptiva because of the risk of a serious brain infection. Following the recall, the medicine will no longer be available anywhere in the European Union.
|
| 
